



Curriculum Vitae

Personal information **Evangelia Yannaki**

Work experience

- 11/2017 - present Affiliate Professor of Medicine, University of Washington, Seattle
- 07/2011- present Director, HCT Unit-Gene and Cell Therapy Center, G. Papanikolaou Hospital, Thessaloniki
- 01/2011 - 10/2017 Affiliate Associate Professor of Medicine, University of Washington, Seattle
- 04/2006 - 07/2012 Senior Attending Hematologist, HCT Unit, G. Papanikolaou Hospital, Thessaloniki
- 02/2004- present Medical Director of the Gene and Cell Therapy Center, G.Papanikolaou Hospital, Thessaloniki
- 09/2000 - 04/2006 Attending Hematologist, HCT Unit, G. Papanikolaou Hospital, Thessaloniki
- 08/2000 - 01/2011 Affiliate Assistant Professor, University of Washington, Seattle
- 04/1998 - 08/2000 Visiting Scientist, Medical Genetics, University of Washington, Seattle, USA
- 06/1997 - 04/1998 Attending Hematologist, HCT Unit, G. Papanikolaou Hospital, Thessaloniki
- 03/1992 - 03/1996 Residency, Hematology, G.Papanikolaou Hospital, Thessaloniki, Greece
- 08/1989 - 02/1992 Internship, General Hospital of Drama, Drama, Greece
- 06/1988 - 08/1989 Community doctor, Health Center of Tsotyli, Kozani, Greece

Education and training

- 01/2000 - 07/2007 PhD Gene Therapy, University of Crete, Greece
- 04/1998 - 08/2000 Visiting Scientist Gene Therapy, University of Washington, Seattle
- 02/1990 - 04/1997 Specialty Hematology, Hematology Greek Boards Certification
- 09/1981 - 04/1988 MD Medicine, Aristotelian University of Thessaloniki, Greece

Additional information

Publications

Complete List of Published Work in : My Bibliography (81 publications, h-index 27):
<https://www.ncbi.nlm.nih.gov/myncbi/1LU1itdKyqqOp/bibliography/public/>

Projects

Experience in clinical trials

| Year | Sponsor/Study phase | CODE-TITLE | Role |
|------------|----------------------------------|---|------------------------|
| 2021- | Investigator-sponsored / Ph I/II | COV-2_STs-001: Generation of SARS-CoV-2-specific T-cells from convalescent donors and administration into high-risk COVID-19 patients | Principal Investigator |
| 2020 - | Investigator-sponsored / Ph I/II | Penta-STs-001: Pentavalent-specific T-cells for the treatment of ADV, CMV, EBV, BKV and Aspergillus Fumigatus infections post allogeneic hematopoietic cell transplantation | Principal Investigator |
| 2019 - | Investigator-sponsored / Ph I-II | Tri-VSTs-001: Tri-virus-specific T-cells for the treatment of CMV, EBV and BKV reactivations of allo-transplanted patients | Principal Investigator |
| 2020- | BlueBirdbio / ph-III | Longterm Follow-up of Subjects With Hemoglobinopathies Treated with ex vivo gene therapy using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector | Principal Investigator |
| 2018 -2021 | BlueBirdbio / ph-III | HGB-212: A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β -Thalassemia, who have a β^0/β^0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral β A-T87Q-Globin Vector in Subjects \leq 50 Years of Age (ongoing) | Principal Investigator |
| 2007-2010 | Investigator-sponsored / Ph I-II | NIH/NHLBI: Stem Cell Gene Therapy for Hemoglobinopathies "Mobilization study with G-CSF \pm Hydroxyurea pretreatment for thalassemia gene therapy" | Principal Investigator |
| 2010-2012 | Investigator-sponsored / Ph I-II | NIH/NHLBI: Program of Excellence in Gene Therapy "Mobilization study with Plerixafor \pm G-CSF for thalassemia gene therapy" | Principal Investigator |
| 2010-2017 | MolMed / ph-III | TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia | Principal Investigator |

Research Activities/Projects

IMUNOGENETIC PROFILE OF PATHOGEN-SPECIFIC T CELLS IN THE CONTEXT OF ADOPTIVE IMMUNOTHERAPY
EPIGENETIC SILENCING OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY
In vivo PRIME EDITING IN HUMANIZED MOUSE MODELS OF B-HEMOGLOBINOPATHIES
IN VIVO BASE EDITING TO INDUCE A -113A>G HPFH MUTATION IN HUMANIZED MOUSE MODELS OF B-HEMOGLOBINOPATHIES
EPIGENETICALLY-MEDIATED REACTIVATION OF GAMMA GLOBIN EXPRESSION IN AN IMMORTALIZED HUMAN ERYTHROID PROGENITOR CELL LINE
SYNTHETIC ERYTHROID ENHANCERS FOR SUCCESSFUL REPLACEMENT of microLCR for GENE THERAPY VECTORS FOR BETA-HEMOGLOBINOPATHIES
NOVEL GENE THERAPY VECTORS FOR BETA-HEMOGLOBINOPATHIES incorporating A SELECTIVE EXPANSION CASSETTE

Memberships

Professional Memberships

- 1997-present Hellenic Society of Hematology
- 1998-2013 American Society of Hematology
- 1998-present American Society of Gene and Cell Therapy
- 2016-present European Society of Gene and Cell Therapy
- 2002-present European Group for Blood and Marrow Transplantation
- 2012-2015 Hematologic and Immunologic Gene and Cell therapy Committee of the American Society of Gene and Cell Therapy
- 2016-2018 National Deputy Representative in EU for Tissue and Cell Transplantation Issues–state appointment
- 2015- 2020 International Committee of the American Society of Gene and Cell Therapy (two consecutive terms)
- 2015-present Hellenic Society of Gene Therapy and Regenerative Medicine (Founding member 2015, Elected: member of the Board 2015-2017, General Secretary of the Board 2017-2019, Vice President 2019-2021, President 2021-2023)
- 2018-2020 Hellenic Society of Hematology (Member of the Board of Directors)
- 2020-2020 Member of the Advisory Committee of the National Organization of Transplants (EOM) on the definition of Terms and Requirements for the Organizations Supplying Cells and Tissues

Awards/Scientific recognitions

- George Papanicolaou Hospital: Research mobility fellowship [Host Institute : Division of Medical Genetics, University of Washington (1998-2000)]
- Hellenic Society of Hematology 2020, 2019, 2017, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008 : best submitted abstract award
- Hellenic Society of Hematology 2007 : Arkagathos Goutas award
- Hellenic Society of Hematology 2018 : George Stamatoyannopoulos award
- European School of Haematology, – EHA Association, 2008: Travel award (*A. Papadopoulou*)
- International Society of Cellular Therapy, 2011, 2022: Young Investigator Award (2011, *A. Papadopoulou*), Technologist Award (2022, *A. Papadopoulou*)
- Greek Ministry of Education – General Secretariat of Research and Technology, 2012 : Excellence Award
- Medical Association of Northern Greece, 2014 : 1st award of the best submitted paper (*G.Karponi*)
- Hellenic Medical Society 2016, 2017, 2018, 2019, 2021, 2022 : 2nd award for submitted abstract (*K.Koukoulis 2016*), Sotiris Papastamatis award (*N.Zogas 2016*) for the best submitted paper, Metropolitan award in Hemopoiesis-Hematotherapy (*I.Vallianou, 2018 and P.Christophi, 2022*), 2nd award for Applied Science and *A.Georgakopoulou*, 2018), Basic Research Award (*P.Papayanni*, 2019),
- Greek State Scholarships Foundation-IKY; 2014-2015, Siemens Programme-Postdoc Fellowships of Excellence (*A.Papadopoulou*)
- Hellenic Society of Gene Therapy and Regenerative Medicine Scholarship, 2016-2017 : “T-cell immunotherapy against pathogens and leukemia post allo-transplantation (*K.Koukoulis*)
- American Society of Gene and Cell Therapy 2014, 2016, 2017: Travel award (*G.Karponi*) / Outstanding poster presentation award (*A.Papadopoulou-K.Koukoulis*) / Meritorious Abstract Travel Award (*A.Papadopoulou*)
- Hellenic Foundation of Research and Innovation (ELIDEK) 2017 and 2020 and 2023: Fellowship (*P.Papayanni, P.Christophi, K.Paschoudi*)
- Foundation of National Fellowships (IKY) 2018 : Fellowship (*M.Alvanou*), Mobility Fellowship (*A.Georgakopoulou*, Host Institute : Medical Genetics Dept, University of Washington, Seattle)
- European Hematology Association 2014, 2019: Travel awards (*G.Karponi, C.Pantazi*)
- International Society for Blood Transfusion 2019: Harold Gunson Fellowship (*G.Kaltsounis*)
- European Hematology Association 2018, 2019, 2020 : Advanced Research Grant (*A.Papadopoulou 2018, N.Psatha 2020*) / Mobility Grant (*P.Papayanni*, 2019, Host Institute: [Division of Regenerative Medicine, Stem Cells and Gene Therapy](#), San Raffaele, Milan, Italy)
- European Society of Gene and Cell Therapy 2019, 2022 : Travel award (*P.Papayanni*), Travel award (*P.Christophi*)
- HealthCare Business Awards 2021 : Gold award for “T-cell adoptive immunotherapy for viral infections, including COVID-19”

Invited speaker at international congresses 2018-2022

- **Speaker** “Challenges to global access to gene therapy for thalassemia”, 11th Cooley’s Anemia Foundation Meeting, 17-20 Oct 2022, New York
- **Speaker** “Topics of Specific Interest in Medical Mycology : Cell therapy in the immunocompromised patients”, 2nd Balkan Conference on medical Mycology, Oct 6-8 2022, Thessaloniki
- **Speaker** “Thematic debate: Gene addition or gene editing for hemoglobinopathies? – The gene addition side” EHA, June 9-17/2022, Vienna
- **Speaker** “T-cell immunotherapy against leukemia and viruses, including SARS-COV2”, ESGCT Spring School 2022, 27-29 April 2022, Athens
- **Chair** “Curative Approaches in Haemoglobin Disorders”, 15th International Conference on Thalassemia &

Other Haemoglobinopathies, Thalassemia International Federation, Virtual 19-21 November 2021

- **Speaker** "Update on gene modification studies with focus on cell apheresis/collection", Session : Cellular Therapy. American Society For Apheresis (ASFA), Virtual event May 12-15 2021
- **Chair and Speaker** «Introducing Innovation in the Care and Cure of Haemoglobin Disorders: Gene Therapy for Thalassaemia & Sickle Cell Disease». Thalassemia International Federation, European Thalassemia & Sickle Cell Disease symposium, Virtual Event 11-13/12/2020
- **Chair & Speaker:** "Gene Therapy for Beta-Thalassemia: The Future is Now" EBMT Live Educational Symposium, European Society for Blood and Marrow Transplantation (EBMT) virtual meeting, 29/08-1/09/2020
- **Speaker** «Gene therapy: the changing landscape in the treatment of thalassemia» 3rd Greco-Israeli Hematology Meeting, 10-12/09/ 2020
- **Speaker – Pannelist :** "β-Thalassemia Gene Therapy From Research to Real World: Applying Lessons Learned" Expert Round Table Discussion, EHA Virtual Edition 11-21/06/2020.
- **Speaker** "Advances in genome-based treatments – approaching the end?" High-Level thalassemia and Sickle Cell Disease Healthcare Professionals Summit, Thalassemia International Federation, 01-02 Nov, 2019, Thessaloniki
- **Speaker** «George Stamatoyannopoulos: his impact on Greek science». George Stamatoyannopoulos Memorial Symposium – French Hutchinson Cancer Center, Sept 16th, 2019, Seattle
- **Speaker** "Setting the technical scene : Genetic therapies: what are they and how to deliver them?" Health for all : Gene and Cell Therapies in Universal Health Coverage / 72nd World Health Assembly, Side Event of Thalassemia International Federation, May 22, 2019, Geneve
- **Chair**, Session "How do I...mobilize and collect stem cells in patients with TDT and SCD for optimal apheresis" 45th Annual Meeting of the European Society for Blood and Marrow Transplantation-EBMT, 24-27 March 2019, Frankfurt, Germany
- **Chair** "From Multinational Trials Towards Global Gene Therapy Products: Approval Process, Manufacturing, Distribution, Follow-up and Ethics", Scientific Symposium 27th Annual Meeting of the American Society of Gene and Cell Therapy-ASGCT, Chicago, USA, May 16-19, 2018
- **Chair**, Session «CAR T-cells» 1st Greco-Israeli Hematology Meeting, Thessaloniki, April 26-28, 2018.

Other Relevant Information

Research funding

- Altius Institute, Seattle, Joint Program (2022-2024), "Hemoglobin switching using artificial transcription factors" Role : Co-PI
- Altius Institute, Seattle, Joint Program (2022-2024), "The Hellenic DNA" Role : Co-PI
- Committee of Greece 2021, for the celebration of two hundred years after the Hellenic Independence. (2021-2023) "COV-2-specific T-cells from covalent donors as adoptive T-cell immunotherapy for severe COVID-19", Role : PI
- National ACTION: Investigate-Create-Innovate, Cycle B. (2021-2023). " Innovative approaches for T cell immunotherapy post allogeneic hematopoietic cell transplantation" , Role : PI - coordinator
- Hellenic Foundation of Research and Innovation (ELIDEK), (2019-2022). "Ex vivo generation of innovative cellular immunotherapies by pharmacological epigenetic modulation", Role : PI
- Hellenic Society of Hematology (2019-2021)" Tri-virus-specific T-cells for the treatment of infections from CMV, EBV and BKV in patients post allogeneic hematopoietic cell transplantation" Role : PI
- P01 HL053750 Stamatoyannopoulos (2010-2017), NIH/NHLBI "Stem Cell Gene Therapy for Hemoglobinopathies", Role : Co-PI
- GECETHERNET- 09 ΣΥΝ-12-1159 (2013-2015), ESPA, "Cooperation-Action I Greek Ministry of Education – EU "A network for generation of new systems and processes in cell and gene therapy for thalassemia and other common diseases in Greece" , Role : PI
- HERAKLITOS II (2011-2013) Greek Ministry of Education "Cell therapy for liver regeneration in mouse models" Role : PI
- U01 HL066947-06 Stamatoyannopoulos G. (2005-2010) NIH/NHLBI "Program of Excellence in Gene Therapy", Role : Co-PI
- EPAN-Competiveness, Greek Ministry of Development (2004-2006) YB/90 "A network for the development of technology and the application of gene therapy in hematological diseases" Role : PI